Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO) announced highly encouraging six-month postoperative results from the first group of patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens. The results show that clinical outcomes meet and exceed expectations, with all patients experiencing continuing vision improvements and a strong safety profile.
Patients who received the Ocumetics Lens entered the study with very poor vision, including one individual who was legally blind. At six months post-surgery, patients continue to demonstrate improved vision and stable visual acuity. Anecdotally, all patients reported life-changing results from lens implantations, including the ability to read, drive, and live independently again.
“After six months, what stands out most is not just the clinical performance of the Ocumetics Lens, but the profound impact on patients’ quality of life,” said Dean Burns, President and CEO of Ocumetics. “We’re developing a technology that dramatically improves people’s quality of life and we couldn’t be happier.”
The company is leveraging surgeon feedback and patient experience into ongoing product enhancements. Updated lens refinements are currently in manufacturing and testing, supporting the planned initiation of Group Two surgeries. “The measurable improvements in visual acuity and consistency we are seeing at six months give us tremendous confidence as we advance to the next phase of our clinical program,” added Burns.
The Ocumetics Lens is designed to fit within the natural lens compartment of the eye and use the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses. These results reinforce the expected performance of the company’s inaugural accommodating intraocular lens.
Ocumetics will host a webinar on April 22, 2026, at 4:00 PM ET to discuss the six-month study results and updates on the FIH study. Registration is available at www.ocumetics.com/webinar.
